Short Interest in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Increases By 7.8%

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,500,000 shares, a growth of 7.8% from the December 15th total of 2,320,000 shares. Approximately 8.0% of the company’s shares are short sold. Based on an average daily volume of 544,200 shares, the short-interest ratio is currently 4.6 days.

DCPH stock traded up $0.75 during trading on Friday, hitting $67.92. The company had a trading volume of 50,848 shares, compared to its average volume of 660,270. Deciphera Pharmaceuticals has a 1-year low of $19.88 and a 1-year high of $70.00. The firm has a 50-day moving average price of $60.07 and a 200-day moving average price of $40.32. The firm has a market cap of $3.43 billion, a PE ratio of -24.09 and a beta of 2.03.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.09). As a group, research analysts forecast that Deciphera Pharmaceuticals will post -4.11 EPS for the current year.

In other news, insider Daniel Lee Flynn sold 29,820 shares of Deciphera Pharmaceuticals stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $44.34, for a total transaction of $1,322,218.80. Also, insider Christopher John Morl sold 1,650 shares of Deciphera Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $60.02, for a total transaction of $99,033.00. Following the sale, the insider now owns 1,650 shares in the company, valued at $99,033. The disclosure for this sale can be found here. Insiders sold a total of 295,133 shares of company stock valued at $14,891,278 in the last ninety days. Company insiders own 7.02% of the company’s stock.

Several large investors have recently made changes to their positions in DCPH. Redmile Group LLC boosted its stake in shares of Deciphera Pharmaceuticals by 115.0% during the 3rd quarter. Redmile Group LLC now owns 4,780,898 shares of the company’s stock worth $162,264,000 after acquiring an additional 2,557,522 shares in the last quarter. Pictet Asset Management Ltd. acquired a new position in Deciphera Pharmaceuticals in the 3rd quarter valued at $15,608,000. BlackRock Inc. raised its holdings in Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock valued at $34,543,000 after acquiring an additional 311,870 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Deciphera Pharmaceuticals in the 2nd quarter valued at $4,606,000. Finally, State Street Corp raised its holdings in Deciphera Pharmaceuticals by 19.7% in the 3rd quarter. State Street Corp now owns 754,236 shares of the company’s stock valued at $25,599,000 after acquiring an additional 124,005 shares during the last quarter. 69.45% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on DCPH. SunTrust Banks began coverage on shares of Deciphera Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $77.00 price objective for the company. JMP Securities reaffirmed a “buy” rating and set a $70.00 price target on shares of Deciphera Pharmaceuticals in a research report on Wednesday. Jefferies Financial Group upped their price target on shares of Deciphera Pharmaceuticals from $53.00 to $77.00 and gave the stock a “buy” rating in a research report on Friday, December 20th. Zacks Investment Research lowered shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, BidaskClub raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the stock. Deciphera Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $57.50.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Recommended Story: Learning About the VIX – Volatility Index

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.